{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:56Z","timestamp":1793730956402,"version":"4.6.1"},"reference-count":180,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Cholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA. The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003705","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:00:09Z","timestamp":1753185609000},"page":"1904-1926","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Targeted therapies and immunotherapies for unresectable cholangiocarcinoma"],"prefix":"10.1097","volume":"138","author":[{"given":"Shengbai","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Punan Hospital in Pudong New District, Shanghai 200125, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyuan","family":"Shentu","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"R1-20250821","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20250821","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20250821","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R4-20250821","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/CM9.0000000000003395","article-title":"Disease burden of biliary tract cancer in 204 countries and territories, 1990-2021: A comprehensive demographic analysis of the Global Burden of Disease Study 2021","volume":"137","author":"Sun","year":"2024","journal-title":"Chin Med J"},{"key":"R5-20250821","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","article-title":"Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database","volume":"16","author":"Yao","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"R6-20250821","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"key":"R7-20250821","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-20250821","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20250821","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R10-20250821","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jb\/mvq121","article-title":"Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease","volume":"149","author":"Itoh","year":"2011","journal-title":"J Biochem"},{"key":"R11-20250821","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"R12-20250821","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"R13-20250821","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"R14-20250821","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 Inhibition in Cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu Rev Med"},{"key":"R15-20250821","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"R16-20250821","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R17-20250821","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"R18-20250821","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1002\/cam4.5798","article-title":"FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies","volume":"12","author":"Fujiwara","year":"2023","journal-title":"Cancer Med"},{"key":"R19-20250821","doi-asserted-by":"crossref","first-page":"e2100414","DOI":"10.1200\/PO.21.00414","article-title":"Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF\/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response","volume":"6","author":"Bibeau","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"R20-20250821","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"R21-20250821","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/cam4.5273","article-title":"Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Med"},{"key":"R22-20250821","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"R23-20250821","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"key":"R24-20250821","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"R25-20250821","doi-asserted-by":"crossref","first-page":"106037","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"R26-20250821","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R27-20250821","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"key":"R28-20250821","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"key":"R29-20250821","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"R30-20250821","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"R31-20250821","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF\/FGFR Aberrations: A Phase I Dose-Expansion Study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"R32-20250821","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"R33-20250821","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-23-1042","article-title":"FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements","volume":"29","author":"Gandhy","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R34-20250821","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"R35-20250821","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"R36-20250821","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"key":"R37-20250821","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4_suppl","key":"R38-20250821","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2023.41.4_suppl.610","article-title":"Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (<i>FGFRalt<\/i>) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results","volume":"41","author":"Pant","year":"2023","journal-title":"JCO"},{"issue":"15_suppl","key":"R39-20250821","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"JCO"},{"issue":"4_suppl","key":"R40-20250821","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1200\/JCO.2022.40.4_suppl.430","article-title":"Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations","volume":"40","author":"Feng","year":"2022","journal-title":"JCO"},{"key":"R41-20250821","doi-asserted-by":"crossref","first-page":"e0162594","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLoS One"},{"key":"R42-20250821","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"R43-20250821","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"R44-20250821","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"JCO"},{"key":"R45-20250821","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R46-20250821","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann Oncol"},{"key":"R47-20250821","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2017.03.003","article-title":"Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions","volume":"177","author":"Upadhyay","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R48-20250821","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"R49-20250821","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"R50-20250821","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"key":"R51-20250821","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"R52-20250821","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R53-20250821","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"R54-20250821","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"R55-20250821","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R56-20250821","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R57-20250821","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"R58-20250821","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R59-20250821","doi-asserted-by":"crossref","first-page":"17588359231171574","DOI":"10.1177\/17588359231171574","article-title":"Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience","volume":"15","author":"Rimini","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"R60-20250821","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00401-017-1677-y","article-title":"Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo","volume":"133","author":"Pusch","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R61-20250821","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"key":"R62-20250821","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1158\/1078-0432.CCR-20-4256","article-title":"Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors","volume":"27","author":"Wick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R63-20250821","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: A review","volume":"32","author":"Ritterhouse","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"R64-20250821","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod Pathol"},{"key":"R65-20250821","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.humpath.2013.07.026","article-title":"The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome","volume":"44","author":"Robertson","year":"2013","journal-title":"Hum Pathol"},{"key":"R66-20250821","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"R67-20250821","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R68-20250821","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R69-20250821","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"R70-20250821","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R71-20250821","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"R72-20250821","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"R73-20250821","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R74-20250821","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"R75-20250821","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"R76-20250821","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann Oncol"},{"key":"R77-20250821","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"R78-20250821","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/gast.2002.32410","article-title":"Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line","volume":"122","author":"Yoon","year":"2002","journal-title":"Gastroenterology"},{"key":"R79-20250821","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jhep.2004.07.016","article-title":"Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells","volume":"41","author":"Yoon","year":"2004","journal-title":"J Hepatol"},{"key":"R80-20250821","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"R81-20250821","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"R82-20250821","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur J Cancer"},{"key":"R83-20250821","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"R84-20250821","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/annonc\/mdm006","article-title":"Gene amplification and protein overexpression of HER-2\/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients","volume":"18","author":"Kim","year":"2007","journal-title":"Ann Oncol"},{"key":"R85-20250821","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"R86-20250821","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R87-20250821","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino","year":"2010","journal-title":"BMC Cancer"},{"key":"R88-20250821","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00280-006-0389-0","article-title":"Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial","volume":"60","author":"Dragovich","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R89-20250821","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J Clin Oncol"},{"key":"R90-20250821","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"key":"R91-20250821","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"R92-20250821","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000111117","article-title":"Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas","volume":"72","author":"Paule","year":"2007","journal-title":"Oncology"},{"key":"R93-20250821","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"key":"R94-20250821","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"R95-20250821","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"R96-20250821","doi-asserted-by":"crossref","first-page":"25369","DOI":"10.1038\/srep25369","article-title":"Expression levels of ROS1\/ALK\/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci Rep"},{"key":"R97-20250821","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/annonc\/mdt337","article-title":"Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology","volume":"24","author":"Borbath","year":"2013","journal-title":"Ann Oncol"},{"key":"R98-20250821","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1016\/j.ejca.2013.07.143","article-title":"Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study","volume":"49","author":"Rubovszky","year":"2013","journal-title":"Eur J Cancer"},{"key":"R99-20250821","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann Oncol"},{"key":"R100-20250821","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"R101-20250821","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ijc.33509","article-title":"Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations","volume":"149","author":"Amin","year":"2021","journal-title":"Int J Cancer"},{"key":"R102-20250821","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"Sohal","year":"2013","journal-title":"Ann Oncol"},{"key":"R103-20250821","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R104-20250821","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2015.07.041","article-title":"A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours","volume":"51","author":"Suder","year":"2015","journal-title":"Eur J Cancer"},{"key":"R105-20250821","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12885-018-5223-7","article-title":"Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program","volume":"19","author":"Moehler","year":"2019","journal-title":"BMC Cancer"},{"key":"R106-20250821","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R107-20250821","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","article-title":"Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer","volume":"13","author":"Rizell","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"R108-20250821","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12885-017-3196-6","article-title":"Prospective phase II trial of everolimus in PIK3CA amplification\/mutation and\/or PTEN loss patients with advanced solid tumors refractory to standard therapy","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"key":"R109-20250821","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10637-018-0600-2","article-title":"Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer","volume":"36","author":"Finn","year":"2018","journal-title":"Invest New Drugs"},{"key":"R110-20250821","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cncr.33364","article-title":"Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers","volume":"127","author":"Tan","year":"2021","journal-title":"Cancer"},{"key":"R111-20250821","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R112-20250821","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"R113-20250821","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R114-20250821","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"R115-20250821","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"R116-20250821","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"R117-20250821","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"R118-20250821","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"R119-20250821","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R120-20250821","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R121-20250821","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"R122-20250821","first-page":"2257","article-title":"Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas","volume":"19","author":"Hida","year":"1999","journal-title":"Anticancer Res"},{"key":"R123-20250821","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"R124-20250821","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"key":"R125-20250821","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000479970","article-title":"Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study","volume":"94","author":"Larsen","year":"2018","journal-title":"Oncology"},{"key":"R126-20250821","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/COC.0000000000000347","article-title":"A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer","volume":"41","author":"Iyer","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"R127-20250821","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1158\/1078-0432.CCR-21-3548","article-title":"Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R128-20250821","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","article-title":"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study","volume":"22","author":"Valle","year":"2021","journal-title":"Lancet Oncol"},{"key":"R129-20250821","doi-asserted-by":"crossref","first-page":"17588359211039047","DOI":"10.1177\/17588359211039047","article-title":"Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study","volume":"13","author":"Wang","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R130-20250821","doi-asserted-by":"crossref","first-page":"659217","DOI":"10.3389\/fonc.2021.659217","article-title":"Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"R131-20250821","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"R132-20250821","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest New Drugs"},{"key":"R133-20250821","doi-asserted-by":"crossref","first-page":"17246","DOI":"10.18632\/oncotarget.12825","article-title":"Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study","volume":"8","author":"Luo","year":"2017","journal-title":"Oncotarget"},{"key":"R134-20250821","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"R135-20250821","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur J Cancer"},{"key":"R136-20250821","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2011.11.017","article-title":"A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study","volume":"48","author":"Yi","year":"2012","journal-title":"Eur J Cancer"},{"key":"R137-20250821","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/JCO.2009.26.9696","article-title":"A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors","volume":"28","author":"Sweeney","year":"2010","journal-title":"J Clin Oncol"},{"key":"R138-20250821","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"R139-20250821","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"R140-20250821","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"key":"R141-20250821","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann Oncol"},{"key":"R142-20250821","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"key":"R143-20250821","doi-asserted-by":"crossref","first-page":"785535","DOI":"10.3389\/fonc.2022.785535","article-title":"Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R144-20250821","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"R145-20250821","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10637-015-0316-5","article-title":"Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers","volume":"34","author":"Kessler","year":"2016","journal-title":"Invest New Drugs"},{"key":"R146-20250821","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann Oncol"},{"key":"R147-20250821","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune Checkpoint Inhibitors: Basics and Challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem"},{"key":"R148-20250821","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"R149-20250821","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4_suppl","key":"R150-20250821","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"JCO"},{"key":"R151-20250821","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R152-20250821","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncologist"},{"key":"R153-20250821","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R154-20250821","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"R155-20250821","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"R156-20250821","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R157-20250821","doi-asserted-by":"crossref","first-page":"e000367","DOI":"10.1136\/jitc-2019-000367","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study","volume":"8","author":"Feng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R158-20250821","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"R159-20250821","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-022-10373-1","article-title":"A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO)","volume":"22","author":"Elias","year":"2022","journal-title":"BMC Cancer"},{"key":"R160-20250821","doi-asserted-by":"crossref","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R161-20250821","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/ijc.33751","article-title":"Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial","volume":"149","author":"Chen","year":"2021","journal-title":"Int J Cancer"},{"key":"R162-20250821","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s00262-022-03160-1","article-title":"Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers","volume":"71","author":"Zheng","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R163-20250821","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/hep.30482","article-title":"Tremelimumab in Combination With Microwave Ablation in Patients With Refractory\u00a0Biliary Tract Cancer","volume":"69","author":"Xie","year":"2019","journal-title":"Hepatology"},{"key":"R164-20250821","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"R165-20250821","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","article-title":"Principles of adoptive T cell therapy in cancer","volume":"41","author":"Met","year":"2019","journal-title":"Semin Immunopathol"},{"key":"R166-20250821","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R167-20250821","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"R168-20250821","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jvir.2021.09.012","article-title":"Clinical Safety and Efficacy of Locoregional Therapy Combined with Adoptive Transfer of Allogeneic \u03b3\u03b4 T Cells for Advanced Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"33","author":"Zhang","year":"2022","journal-title":"J Vasc Interv Radiol"},{"key":"R169-20250821","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R170-20250821","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.32548","article-title":"Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis","volume":"77","author":"Zhou","year":"2023","journal-title":"Hepatology"},{"key":"R171-20250821","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur J Cancer"},{"key":"R172-20250821","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.24.00337","article-title":"Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial","volume":"43","author":"Macarulla","year":"2025","journal-title":"J Clin Oncol"},{"key":"R173-20250821","doi-asserted-by":"crossref","first-page":"e002191","DOI":"10.1136\/jitc-2020-002191","article-title":"Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib\/II trial","volume":"9","author":"Mei","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R174-20250821","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"R175-20250821","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"R176-20250821","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"R177-20250821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-021-01100-3","article-title":"FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma","volume":"23","author":"King","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R178-20250821","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"R179-20250821","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"R180-20250821","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:01:02Z","timestamp":1755748862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":180,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003705","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"2024-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}